Systemic inflammation is associated with circulating cell death released keratin 18 fragments in colorectal cancer.


Journal

Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
24 06 2020
Historique:
entrez: 14 9 2020
pubmed: 15 9 2020
medline: 15 9 2020
Statut: epublish

Résumé

Systemic inflammation is a stage-independent marker of poor prognosis in colorectal cancer (CRC), activated in a complex, multifactorial process. It has been proposed that one of the main factors driving systemic inflammation may be tumor necrosis. Keratin 18 (KRT18) fragments are released from dead cells and their serum levels are markers for apoptotic and necrotic cell death. In CRC, high KRT18 levels associate with advanced disease, but their relationship with tumor necrosis and systemic inflammation is unknown. In this study, serum total soluble KRT18 (tKRT18) and apoptosis-related, caspase-cleaved fragment (aKRT18) levels were measured preoperatively from 328 CRC patients, and their difference was calculated to assess necrosis related KRT18 (nKRT18) levels. The relationships of these markers with tumor necrosis, clinicopathologic features, systemic inflammation markers (C-reactive protein, albumin, and 13 cytokines), and survival were analyzed. High serum tKRT18, aKRT18, and nKRT18 levels showed association with a higher extent of tumor necrosis, distant metastasis, and increased levels of several markers of systemic inflammation, including CXCL8. High serum tKRT18 (multivariable HR 1.94, 95% CI 1.28-2.95,

Identifiants

pubmed: 32923147
doi: 10.1080/2162402X.2020.1783046
pii: 1783046
pmc: PMC7458668
doi:

Substances chimiques

Keratin-18 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1783046

Informations de copyright

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Anticancer Res. 2013 Mar;33(3):1099-105
pubmed: 23482787
Hum Pathol. 2015 Mar;46(3):434-42
pubmed: 25623077
Int Immunopharmacol. 2010 Jul;10(7):719-22
pubmed: 20362077
Nat Cell Biol. 2014 Aug;16(8):717-27
pubmed: 25082194
Biochim Biophys Acta. 2011 Dec;1812(12):1601-6
pubmed: 21914473
Ann Surg. 2016 Feb;263(2):326-36
pubmed: 25575264
Br J Cancer. 2009 Aug 4;101(3):410-7
pubmed: 19603019
Eur J Cancer. 2005 Nov;41(17):2645-54
pubmed: 16239109
Int J Cancer. 2016 Jul 1;139(1):112-21
pubmed: 26874795
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Clin Transl Oncol. 2012 May;14(5):356-61
pubmed: 22551541
Sci Rep. 2018 Jan 18;8(1):1126
pubmed: 29348549
Histochem Cell Biol. 2008 Jun;129(6):705-33
pubmed: 18461349
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
Virchows Arch. 2012 May;460(5):455-65
pubmed: 22527018
Br J Surg. 2012 Feb;99(2):287-94
pubmed: 22086662
Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1103-9
pubmed: 19769633
Br J Cancer. 2016 Jun 14;114(12):1334-42
pubmed: 27195424
Sci Rep. 2017 Dec 1;7(1):16717
pubmed: 29196718
Cancer Res. 2004 Mar 1;64(5):1751-6
pubmed: 14996736
BMC Cancer. 2009 Mar 23;9:88
pubmed: 19302716
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S359-62
pubmed: 16507409
World J Gastroenterol. 2019 Aug 21;25(31):4383-4404
pubmed: 31496619
Br J Cancer. 2012 Oct 23;107(9):1518-24
pubmed: 22996610
Oncotarget. 2018 Apr 6;9(26):18224-18238
pubmed: 29719601
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Colorectal Dis. 2007 Aug;22(8):881-6
pubmed: 17245566
Br J Cancer. 2014 Oct 14;111(8):1605-13
pubmed: 25137019
Virchows Arch. 2015 Jan;466(1):5-12
pubmed: 25395067
Int J Cancer. 2014 May 1;134(9):2126-35
pubmed: 24154855
Virchows Arch. 2014 Jun;464(6):637-43
pubmed: 24722974
Lung Cancer. 2007 Jun;56(3):399-404
pubmed: 17316892
J Clin Invest. 2009 Jul;119(7):1794-805
pubmed: 19587454
Int J Cancer. 2012 Aug 15;131(4):E463-74
pubmed: 21918979
Br J Cancer. 2013 Jul 9;109(1):131-7
pubmed: 23756867
Br J Cancer. 2012 Nov 6;107(10):1729-36
pubmed: 23059742
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
J Cell Biol. 1997 Sep 22;138(6):1379-94
pubmed: 9298992
Br J Cancer. 2013 Oct 1;109(7):1839-47
pubmed: 24008661
Br J Cancer. 2010 Feb 2;102(3):577-82
pubmed: 20051949
Front Physiol. 2012 Oct 19;3:56
pubmed: 23091461
Nat Rev Endocrinol. 2018 Dec;15(1):9-20
pubmed: 30464312
Int Immunopharmacol. 2009 May;9(5):645-8
pubmed: 19249390
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610
Exp Cell Res. 2004 Jul 1;297(1):11-26
pubmed: 15194421
Hum Pathol. 2010 Dec;41(12):1749-57
pubmed: 20869096

Auteurs

Päivi Sirniö (P)

Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90014, Finland.
Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.

Juha P Väyrynen (JP)

Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90014, Finland.
Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Shivaprakash J Mutt (SJ)

Research Unit of Biomedicine and Biocenter Oulu, Department of Physiology, University of Oulu, Oulu 90014, Finland.

Karl-Heinz Herzig (KH)

Research Unit of Biomedicine and Biocenter Oulu, Department of Physiology, University of Oulu, Oulu 90014, Finland.
Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland.

Jaroslaw Walkowiak (J)

Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland.

Kai Klintrup (K)

Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.
Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, POB 5000, Oulu, Finland.

Jyrki Mäkelä (J)

Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.
Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, POB 5000, Oulu, Finland.

Tuomo J Karttunen (TJ)

Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90014, Finland.
Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.

Markus J Mäkinen (MJ)

Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90014, Finland.
Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.

Anne Tuomisto (A)

Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90014, Finland.
Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90029, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH